BiotechTube

Cholic Acids

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Infantile Refsum's Disease

Conditions

Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy, Peroxisomal Disorders, Cholestasis

Trial Timeline

Jan 1, 1992 → Dec 1, 2009

NCT ID
NCT00007020

About Cholic Acids

Cholic Acids is a phase 3 stage product being developed by Mirum Pharmaceuticals for Infantile Refsum's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00007020. Target conditions include Infantile Refsum's Disease, Zellweger Syndrome, Adrenoleukodystrophy.

What happened to similar drugs?

3 of 6 similar drugs in Infantile Refsum's Disease were approved

Approved (3) Terminated (2) Active (3)
✅alglucosidase alfa + alglucosidase alfaSanofiApproved
✅Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
✅VigabatrinLundbeckApproved
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄GWP42003-PJazz PharmaceuticalsPhase 3
🔄Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00007020Phase 3Completed

Competing Products

16 competing products in Infantile Refsum's Disease

See all competitors
ProductCompanyStageHype Score
TSHA-101Taysha Gene TherapiesPhase 1/2
30
MAS825 + PlaceboNovartisPhase 2
39
alglucosidase alfa + alglucosidase alfaSanofiApproved
35
MyozymeSanofiPhase 2
35
Bacillus Clausii Multi ATB Resist + PlaceboSanofiApproved
43
RadiprodilUCBPhase 2
27
Larotrectinib (Vitrakvi, BAY2757556) + Standard of CareBayerPre-clinical
23
Sabril®LundbeckPre-clinical
23
VigabatrinLundbeckApproved
32
NusinersenBiogenPre-clinical
23
GWP42003-PJazz PharmaceuticalsPhase 3
37
GWP42003-PJazz PharmaceuticalsPhase 3
37
Cerliponase AlfaBioMarin PharmaceuticalPre-clinical
27
Cipaglucosidase alfa + MiglustatAmicus TherapeuticsPhase 3
44
ATB200 + AT2221Amicus TherapeuticsPre-clinical
27
RP-L401Rocket PharmaceuticalsPhase 1
11